Compare MCBS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | ASMB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.1M | 553.6M |
| IPO Year | 2019 | 2010 |
| Metric | MCBS | ASMB |
|---|---|---|
| Price | $28.36 | $36.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $31.00 | ★ $43.40 |
| AVG Volume (30 Days) | 51.9K | ★ 124.4K |
| Earning Date | 01-20-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 11.15 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $147,349,000.00 | $37,191,000.00 |
| Revenue This Year | $13.89 | $42.01 |
| Revenue Next Year | $33.10 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | 8.69 | ★ 31.30 |
| 52 Week Low | $24.24 | $7.75 |
| 52 Week High | $35.45 | $39.71 |
| Indicator | MCBS | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 71.29 | 57.82 |
| Support Level | $27.04 | $35.05 |
| Resistance Level | $27.48 | $38.82 |
| Average True Range (ATR) | 0.60 | 1.91 |
| MACD | 0.26 | -0.32 |
| Stochastic Oscillator | 98.38 | 42.70 |
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.